Drug Profile


Alternative Names: AZD-1722; RDX-5791; Tenapanor hydrochloride

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ardelyx
  • Developer Ardelyx; AstraZeneca
  • Class Benzylisoquinolines; Gastrokinetics; Irritable bowel syndrome therapies; Small molecules; Sulfonamides
  • Mechanism of Action Fibroblast growth factor 23 expression inhibitors; Sodium-hydrogen exchanger 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperphosphataemia; Irritable bowel syndrome
  • Phase II Renal failure
  • No development reported Heart failure

Most Recent Events

  • 09 Aug 2017 Ardelyx completes enrolment in the phase III T3MPO-2 and T3MPO-3 trials for Irritable bowel syndrome with constipation in USA before August 2017
  • 09 Aug 2017 Ardelyx plans a phase III trial for Hyperphosphataemia
  • 12 May 2017 Positive topline efficacy and safety data from the phase III T3MPO-1 trial in irritable bowel syndrome with constipation released by Ardelyx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top